Capital Partners Ii, Llcenr... Net Worth

The estimated Net Worth of Capital Partners Ii, Llcenr... is at least $13.7 Миллион dollars as of 25 July 2017. Capital Llcenr owns over 215,000 units of Kala Bio stock worth over $13,671,095 and over the last 7 years Capital sold KALA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Llcenr KALA stock SEC Form 4 insiders trading

Capital has made over 1 trades of the Kala Bio stock since 2017, according to the Form 4 filled with the SEC. Most recently Capital bought 215,000 units of KALA stock worth $3,225,000 on 25 July 2017.

The largest trade Capital's ever made was buying 215,000 units of Kala Bio stock on 25 July 2017 worth over $3,225,000. On average, Capital trades about 215,000 units every 0 days since 2017. As of 25 July 2017 Capital still owns at least 2,270,946 units of Kala Bio stock.

You can see the complete history of Capital Llcenr stock trades at the bottom of the page.

Insiders trading at Kala Bio

Over the last 7 years, insiders at Kala Bio have traded over $2,579,128 worth of Kala Bio stock and bought 23,705,318 units worth $209,975,371 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ... и Rajeev M. Shah. On average, Kala Bio executives and independent directors trade stock every 31 days with the average trade being worth of $2,090,132. The most recent stock trade was executed by Todd Bazemore on 26 June 2024, trading 4,653 units of KALA stock currently worth $22,102.

What does Kala Bio do?

kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.

Complete history of Capital Llcenr stock trades at Kala Bio

Kala Bio executives and stock owners

Kala Bio executives and other stock owners filed with the SEC include:

• Mark Iwicki,
  Chairman of the Board, President, Chief Executive Officer
• Todd Bazemore,
  Chief Operating Officer
• Eric Trachtenberg,
  Chief Compliance Officer, General Counsel, Secretary
• Kim Brazzell,
  Chief Medical Officer
• Mark T. Iwicki,
  Chairman & CEO
• Dr. Kim Brazzell Ph.D.,
  Head of R&D and Chief Medical Officer
• Hongming Chen,
  Chief Scientific Officer
• Todd Bazemore,
  Pres & COO
• Andrew Koven,
  Lead Independent Director
• Rajeev Shah,
  Independent Director
• Gregory Perry,
  Independent Director
• Robert Paull,
  Independent Director
• Howard Rosen,
  Independent Director
• Gregory Grunberg,
  Independent Director
• Hannah Deresiewicz,
  IR Contact Officer
• Mary Reumuth,
  Chief Financial Officer, Treasurer
• James Patnoe,
  Sr. VP of Market Access, Commercial Operations & Pricing
• Vincent Kosewski,
  Sr. VP of Manufacturing & Supply Chain Management
• Michele LaRussa,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Kathleen McCann Kline,
  Sr. VP of Marketing
• Eric L. Trachtenberg,
  Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Jill S. Steier,
  Exec. Director of Investor Relations & Corp. Communications
• Mary Reumuth CPA, CPA,
  CFO & Treasurer
• Dr. Justin Hanes Ph.D.,
  Founder & Chair of the Scientific Advisory Board
• Capital Partners Ii, Llcenr...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Associates, L.L.C.Caxton Co...,
  
• Paulina Hill,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Capital Management, L.P.Ra ...,
  
• Robert I Tepper,
  Director
• Robert Langer,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Michele La Russa,
  Sr. VP, Regulatory and Quality
• C. Daniel Myers,
  
• Marjan Farid,
  
• Capital Management, L.P.Ra ...,
  
• Romulus K Brazzell,
  SEE REMARKS
• Mark S. Blumenkranz,
  
• Darius Kharabi,
  CHIEF BUSINESS OFFICER